Man I've seen so many launch just after PII's are finally completed and top line data is released. And everyone know those companies are going to do a raise for the expensive phase 3's. Most settle back but still usually higher. We could see a move that sticks well enough for the up listing. imo with the Aspire deal they're pretty much ready to head where they need to get things ready for P3 alone but I'm thinking BP will want to get in on a licensing deal at least for one of the brilacidin lines and possibly prurisol.

Just one puts us on the map.

$IPIX